Neumora Therapeutics, Inc.

NasdaqGS:NMRA Stock Report

Market Cap: US$416.8m

Neumora Therapeutics Management

Management criteria checks 2/4

Neumora Therapeutics' CEO is Henry Gosebruch, appointed in Jul 2023, has a tenure of 1.5 years. total yearly compensation is $22.00M, comprised of 1.5% salary and 98.5% bonuses, including company stock and options. directly owns 0.32% of the company’s shares, worth $1.35M. The average tenure of the management team and the board of directors is 2 years and 4.1 years respectively.

Key information

Henry Gosebruch

Chief executive officer

US$22.0m

Total compensation

CEO salary percentage1.5%
CEO tenure1.5yrs
CEO ownership0.3%
Management average tenure2yrs
Board average tenure4.1yrs

Recent management updates

Recent updates

Neumora Therapeutics: Tanking On Disastrous MDD Data, Bounce Back Unlikely

Jan 03

Neumora: Koastal-1 Readout For MDD Treatment Is First Study On Deck

Dec 24

Neumora Therapeutics: A Story Of A Class II Biotech

Oct 16

We're Hopeful That Neumora Therapeutics (NASDAQ:NMRA) Will Use Its Cash Wisely

Jun 18
We're Hopeful That Neumora Therapeutics (NASDAQ:NMRA) Will Use Its Cash Wisely

Neumora: Phase 3 MDD Readout In H2-24 Could Get Ball Rolling

Feb 08

CEO Compensation Analysis

How has Henry Gosebruch's remuneration changed compared to Neumora Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$294m

Jun 30 2024n/an/a

-US$274m

Mar 31 2024n/an/a

-US$254m

Dec 31 2023US$22mUS$338k

-US$236m

Compensation vs Market: Henry's total compensation ($USD22.00M) is above average for companies of similar size in the US market ($USD2.26M).

Compensation vs Earnings: Insufficient data to compare Henry's compensation with company performance.

CEO

Henry Gosebruch (51 yo)

1.5yrs

Tenure

US$21,999,269

Compensation

Mr. Henry O. Gosebruch serves as President, Chief Executive Officer and Director at Neumora Therapeutics, Inc. since July 2023. He serves as an Independent Director at Acelyrin, Inc. since March 17, 2023....

Leadership Team

NamePositionTenureCompensationOwnership
Paul Berns
Co-Founder & Executive Chairman5yrsUS$8.57m4.73%
$ 19.7m
Henry Gosebruch
President1.5yrsUS$22.00m0.32%
$ 1.4m
Jason Duncan
Chief Legal Officer1.1yrsUS$4.41mno data
Robert Lenz
Head of Research & Development1.3yrsUS$13.58m0%
$ 0
Carol Suh
Co-Founder & COO2yrsno data0.18%
$ 747.4k
Joshua Pinto
Chief Financial Officer3.6yrsUS$3.82m0.086%
$ 358.5k
Michael Milligan
Principal Accounting Officerno datano data0.0024%
$ 9.9k
Rajesh Manchanda
Chief Technical Operations Officer1.5yrsno datano data
Nicholas Brandon
Chief Scientific Officer3yrsno datano data
Amy Sullivan
Chief Human Resources Officer2.3yrsno datano data
Lori Houle
Chief Quality Officer3.8yrsno datano data
Daljit Aurora
Chief Strategy Officerno datano data0.071%
$ 295.9k

2.0yrs

Average Tenure

52.5yo

Average Age

Experienced Management: NMRA's management team is considered experienced (2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Paul Berns
Co-Founder & Executive Chairman5yrsUS$8.57m4.73%
$ 19.7m
Henry Gosebruch
President1.5yrsUS$22.00m0.32%
$ 1.4m
Matthew Fust
Independent Director4.1yrsUS$485.53k0.012%
$ 51.9k
Edward Roberts
Member of Scientific Advisory Boardno datano datano data
Kristina Burow
Independent Director5yrsUS$686.60k0.017%
$ 71.2k
Mark Daly
Member of Scientific Advisory Boardno datano datano data
Gaurav Singal
Member of Technology Advisory Boardno datano datano data
Alaa Halawa
Independent Director2.3yrsUS$671.20kno data
Sandeep Datta
Member of Scientific Advisory Boardno datano datano data
John Krystal
Member of Scientific Advisory Boardno datano datano data
Andrew Trister
Member of Technology Advisory Boardno datano datano data
Patrick Sullivan
Member of Scientific Advisory Boardno datano datano data

4.1yrs

Average Tenure

51yo

Average Age

Experienced Board: NMRA's board of directors are considered experienced (4.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 05:00
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Neumora Therapeutics, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBofA Global Research
Charlie YangBofA Global Research
Yatin SunejaGuggenheim Securities, LLC